Clinical data | |
---|---|
Routes of administration | Intravenous |
Drug class | Antibacterial, beta-lactamase inhibitor |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C8H11N3O6S |
Molar mass | 277.25 g·mol−1 |
3D model ( JSmol) | |
| |
|
Durlobactam is a beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter [1] It is an analog of avibactam.
The combination therapy sulbactam/durlobactam was approved for medical use in the United States in May 2023. [1]
Clinical data | |
---|---|
Routes of administration | Intravenous |
Drug class | Antibacterial, beta-lactamase inhibitor |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C8H11N3O6S |
Molar mass | 277.25 g·mol−1 |
3D model ( JSmol) | |
| |
|
Durlobactam is a beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter [1] It is an analog of avibactam.
The combination therapy sulbactam/durlobactam was approved for medical use in the United States in May 2023. [1]